Items Tagged ‘tyrosine kinase inhibitors’

March 3, 2015

Lenvatinib; First Promising Treatment for Refractory Thyroid Cancer Patients in Years


In a pivotal Phase III study published in the New England Journal of Medicine, the oral anti-angiogenic therapy lenvatinib appears to be a very promising new treatment for patients with advanced radioiodine-refractory thyroid cancer. According to the National Cancer Institute, 60,000 people will be diagnosed with thyroid cancer in 2015 and almost 2,000 will die […]

View full entry

Tags: advanced radioiodine-refractory thyroid cancer, lenvatinib, New England Journal of Medicine, phase III, thyroid gland, tyrosine kinase inhibitors